Jonathan Sherman, MD
Cardiovascular Disease · Vail, CONPI 1871695122
Payments from drug & device makers
Across 228 payments — averaging $29.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Boston Scientific$914
- Edwards Lifesciences$472
- Shockwave Medical, Inc$385
- Novartis$380
- Penumbra, Inc.$313
- plus $2K from 28 others
What the payments were for
- Travel & lodging$92114%
- Food & beverage$5,74085%
- Education$671%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 53 | $1,890 |
| Boston Scientific | 34 | $914 |
| Edwards Lifesciences | 15 | $472 |
| Shockwave Medical, Inc | 8 | $385 |
| Novartis | 13 | $380 |
| Penumbra, Inc. | 2 | $313 |
| E.r. Squibb & Sons, L.L.C. | 16 | $273 |
| Amgen | 14 | $248 |
| Abiomed | 7 | $239 |
| Kestra Medical Technology Services, Inc. | 2 | $223 |
| Philips North America LLC | 10 | $180 |
| W. L. Gore & Associates, Inc. | 2 | $177 |
| Johnson & Johnson | 10 | $164 |
| Pfizer | 9 | $142 |
| Impulse Dynamics (USA) Inc. | 1 | $137 |
| Sanofi-aventis U.S. LLC | 6 | $101 |
| Biotronik Inc. | 2 | $82 |
| Gilead | 2 | $43 |
| Heartflow, Inc. | 1 | $37 |
| Abbott | 2 | $32 |
| Astellas Pharma US Inc | 2 | $32 |
| AbbVie | 2 | $31 |
| Boehringer Ingelheim | 2 | $29 |
| Merck | 2 | $27 |
| AstraZeneca | 2 | $23 |
| Baxter Healthcare | 1 | $22 |
| Cleerly, Inc. | 1 | $21 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $21 |
| Cvrx, Inc. | 1 | $18 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Biosense Webster, Inc. | 1 | $15 |
| Actelion Pharmaceuticals US, Inc. | 1 | $14 |
| Lundbeck LLC | 1 | $13 |
| Akcea Therapeutics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CoreValve Evolut$1,235
- Indigo System$313
- OPTIMIZER$274
- EXCLUDER Conformable AAA Endoprosthesis with Active Control$159
- Edwards SAPIEN 3 Transcatheter Heart Valve$133
- Impella$128
- Assure WCD$128
- GENERAL - STRUCTURAL HEART$125
- RESONATE$123
- GENERAL - STENTS$120
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$116
- Watchman$102
- ENTRESTO$101
How this compares
$6,728 in reported general payments places this provider in the 70th percentile of 276 cardiovascular disease providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 176 | $254,584 |
| XareltoRivaroxaban | 68 | $90,979 |
| EntrestoSacubitril/Valsartan | 36 | $46,509 |
| FarxigaDapagliflozin Propanediol | 28 | $23,729 |
| Repatha SyringeEvolocumab | 13 | $22,155 |
| JardianceEmpagliflozin | 17 | $21,416 |
| Repatha SureclickEvolocumab | 13 | $16,612 |
| MultaqDronedarone Hcl | 11 | $16,506 |
| Ranolazine ErRanolazine | 15 | $3,881 |
| Atorvastatin Calcium | 335 | $2,871 |
| Ezetimibe | 101 | $2,344 |
| Metoprolol Succinate | 179 | $2,107 |
| Carvedilol | 182 | $1,978 |
| Losartan Potassium | 144 | $1,267 |
| Metoprolol Tartrate | 144 | $1,214 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $142 | $254,584176 claims |
| Johnson & JohnsonXarelto | $164 | $90,97968 claims |
| NovartisEntresto | $380 | $46,50936 claims |
| AstraZenecaFarxiga | $23 | $23,72928 claims |
| Boehringer IngelheimJardiance | $29 | $21,41617 claims |
| Sanofi-aventis U.S. LLCMultaq | $101 | $16,50611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 276 cardiovascular disease providers in Colorado.
Other cardiovascular disease in Vail
- Gary LuckasenFort Collins$11M
- Payal KohliAurora$1.7M
- Marc BonacaAurora$1.2M
- William SauerAurora$978K
- John AltmanLakewood$797K
- Nampalli VijayDenver$711K
- Brack HattlerAurora$699K
- Lin-Wang DongGreeley$640K
- Jake ChaninDenver$586K
- Andrew FreemanDenver$454K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.